지씨셀

144510KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

42.5 / 100

Reference Date: 2026-07-24

Financial Score8.5 / 40

News Sentiment20.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, Revenue is on a declining trend. Declined 11.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GC Cell is a company primarily engaged in the development and commercialization of cell therapies, specimen testing, cord blood banking, bio-logging, and CDMO services. The company is focusing on the development of NK and T cell therapies and is advancing research on next-generation CAR-NK and CAR-T treatments.

Number of Employees

806people

Average Salary

48.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 42.304.0Point

PBR

1.11Industry Average 1.082.5Point

Higher than industry avg (caution)

ROE

-83.81Industry Average 0.940.0Point

Well below industry avg

Debt Ratio

18.04Industry Average 12.512.0Point

Higher than industry avg (caution)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼6.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼279.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -33.0% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 1Negative 0Average Sentiment Score 80

Positive
지씨셀, 라플레와 면역세포치료 예후 예측 AI 개발 맞손
지씨셀과 라플레의 협력으로 면역세포치료 AI 모델 개발이 진행되어 치료 효과 예측 정확도 향상이 기대된다.
Positive
지씨셀, 'GCC2005' 임상 1상 변경 승인
지씨셀의 'GCC2005' 임상 1상 시험계획 변경 승인으로 치료 가능성 확대 및 안전성 검증에 긍정적 영향.
Positive
“2~3년 기다림 끝” 첨단재생의료 임상 진입 빨라진다…차바이오텍·.....
지씨셀의 첨단 재생의료 임상 진입이 가속화되어 희귀 난치병 환자 치료 접근성이 크게 향상될 것으로 전망됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 13,360Won52-week high 27,50052-week low 12,720

1-month return1.0Point

1m -11.11% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험계획변경승인) (GCC2005의 국내 제 1상 임상시험계획 변경승인)2026-07-20
Neutral자기주식처분결과보고서2026-07-20
Neutral주요사항보고서(자기주식처분결정)2026-06-30